ASP8273 Capsules + ASP8273 Capsules A
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Conditions
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Trial Timeline
Jun 25, 2015 → Jun 9, 2017
NCT ID
NCT02500927About ASP8273 Capsules + ASP8273 Capsules A
ASP8273 Capsules + ASP8273 Capsules A is a phase 2 stage product being developed by Astellas Pharma for EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations. The current trial status is terminated. This product is registered under clinical trial identifier NCT02500927. Target conditions include EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations.
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02500927 | Phase 2 | Terminated |